Klamentin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Klamentin

Klamentin, corresponding to the generic combination Amoxicillin/Clavulanic Acid (Co-amoxiclav), is a sophisticated, prescription-only Broad-spectrum combination antibiotic. Its overall purpose is to provide systemic treatment for bacterial infections by eliminating susceptible pathogens and counteracting common resistance mechanisms. This combination is recognized globally as an essential medicine due to its critical role in managing resistant infections.

Property Description
Active ingredients Amoxicillin, Clavulanic Acid
Form Tablet, Oral Suspension
Pharmacological class β-Lactam Antibiotic / β-Lactamase Inhibitor
Common use Systemic Bacterial Infections
Origin Semi-synthetic (Amoxicillin) / Fermentation-derived (Clavulanic Acid)

What Type of Medicine is Klamentin (Amoxicillin/Clavulanic Acid)?

Klamentin is a fixed-dose combination product containing two essential components. The primary agent, Amoxicillin, is a semi-synthetic penicillin derivative belonging to the β-lactam class of drugs. The combination is clinically recognized for its utility against a wide range of bacterial pathogens, distinguishing it from older, single-agent penicillins. Popular brands sharing this formulation include Augmentin and Amoksiklav, further underscoring its established role in medicine.

Composition and Pharmaceutical Forms

Its two active ingredients are Amoxicillin and Clavulanic Acid. Amoxicillin acts as the primary bacterial-killing agent, while Clavulanic Acid serves as a β-lactamase inhibitor, protecting the antibiotic from degradation. This protective role ensures that the combination effectively extends the antibiotic's activity against strains that produce the β-lactamase enzyme. The medication is prepared for the oral route of administration and is marketed to accommodate various age groups, offering both a film-coated tablet and a palatable powder for oral suspension for patients, such as children, who may struggle with swallowing tablets.

The Purpose of the Dual-Component Design

The rationale for the dual-component design is to ensure a reliable therapeutic outcome by preventing treatment failure caused by resistant bacteria. The synergistic action enhances the drug's efficacy compared to using Amoxicillin alone, effectively broadening its spectrum of activity. This design helps the body by achieving a definitive bactericidal effect against a wider range of pathogens, a key factor when a common use scenario involves treating a suspected β-lactamase-producing bacterial respiratory tract infection.

Regulatory References

  1. World Health Organization (WHO)

What side effects are possible with Klamentin?

Possible side effects and safety information

The safety profile of Klamentin (Amoxicillin/Clavulanic Acid) is defined by officially documented adverse reactions classified by frequency and body system, consistent with regulatory standards. Adverse events are grouped by System-Organ Classes, with the Gastrointestinal Disorders and Skin and Subcutaneous Tissue Disorders being the most frequently documented categories.

Adverse Reaction Frequencies

Side effects are officially classified based on their observed frequency in clinical use:

  • Very Common: Diarrhoea (particularly with the oral suspension formulation).
  • Common: Diarrhoea (with tablets), Nausea, and Mucocutaneous Candidiasis.
  • Uncommon: Vomiting, Indigestion, Dizziness, Headache, Rash, and reversible increases in hepatic transaminases.
  • Rare/Very Rare: These include Erythema Multiforme, reversible changes in blood cell counts (leucopenia, thrombocytopenia), Hepatitis, and Cholestatic Jaundice.

Documented Serious Safety Concerns

The regulatory profile lists several serious adverse reactions, which, although rare, are critical safety limitations. These include potentially fatal Severe Hypersensitivity Reactions (Anaphylaxis) and severe skin disorders known as SCARs (Severe Cutaneous Adverse Reactions), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Additionally, Antibiotic-Associated Colitis and instances of Convulsions are documented safety concerns.

Population-Specific Safety Notes

The medicine is officially contraindicated in individuals with a known history of hypersensitivity to penicillins or a history of Amoxicillin/Clavulanic Acid-associated jaundice or hepatic dysfunction. Hepatic events are reported to occur more frequently in older adults. Regulatory documents also note that the onset of hepatic reactions may be delayed for several weeks after treatment has stopped, and hypersensitivity reactions are more frequently observed at the start of treatment.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Klamentin (Amoxicillin/Clavulanic Acid) describes specific manifestations and the required emergency response in case of overdosage. Overdose may be asymptomatic or present initially with gastrointestinal symptoms, including vomiting, diarrhea, and abdominal pain. Less frequently, documented neurological effects such as drowsiness or hyperactivity may be observed.

Urgent medical attention is required whenever signs of severe manifestations occur. The prescribing information notes that overdosage carries the risk of serious outcomes, including convulsions (seizures) and acute kidney injury. Convulsions are specifically documented as a risk in patients with impaired renal function or those who receive high doses. The potential for amoxicillin crystalluria, which can lead to oliguric renal failure, is also a documented concern.

Management procedures described in official labels emphasize immediate discontinuation of the drug. As no specific antidote is known, treatment is focused on providing symptomatic and supportive measures. This includes maintaining adequate fluid intake and urinary output to reduce the possibility of crystalluria. In cases of very recent ingestion, gastrointestinal decontamination may be considered, and the active components can be removed from circulation via hemodialysis.

Therapeutic Uses of Klamentin

What Klamentin Treats: Main Uses and Benefits

Klamentin (Amoxicillin/Clavulanic Acid) is commonly used for conditions involving bacterial infections of the ears, lungs, sinus, skin, and urinary tract. The combination is applied across domains where additional symptomatic support is needed for bacterial infections, particularly when resistance is suspected. It is relevant in clinical settings that involve acute or unstable symptom patterns, offering supportive relief that helps ease the overall symptom burden.

Klamentin is commonly used across conditions presenting with acute episodes in key areas including the respiratory tract (e.g., severe sinusitis, pneumonia), skin and soft tissues (e.g., cellulitis, wound infections), and the urinary tract (e.g., pyelonephritis). It helps address symptom clusters that may become intense or disruptive, such as persistent fever, painful facial pressure, pronounced swelling, and purulent discharge. This medication supports the patient during difficult episodes by easing distress and assisting with functional support.


“The primary role of this combination is to provide supportive relief and symptomatic assistance against bacterial populations that may be relevant to the combination’s use.”

Quick Fact: Relief for Intense Symptoms
Klamentin is commonly used when symptoms related to systemic imbalance (like fever) and localized discomfort (like pain and swelling) are significantly disruptive, helping to ease the overall symptom load.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Klamentin (Amoxicillin/Clavulanic Acid) eligibility is strictly defined by regulatory documents based on patient medical history, organ function, and age.

Populations That Must Not Use Klamentin (Contraindications)

Use is absolutely contraindicated if a patient has a history of serious hypersensitivity reaction to penicillins, other beta-lactam antibacterial drugs, or any of the medicine’s components. It is also contraindicated for patients with a previous history of cholestatic jaundice or hepatic dysfunction specifically associated with taking Klamentin.

Populations with Restricted or Conditional Eligibility

Regulatory documents require caution and monitoring for patients with existing hepatic impairment. Dosage adjustment is mandatory for patients with renal impairment (kidney function below CrCl leq 30 mL/ min), and some high-strength formulations are not recommended for this group. The medicine should also be avoided in patients with, or suspected of having, Infectious Mononucleosis due to a high risk of rash.

Age and Reproductive Status

Klamentin is established for use in adults and pediatric patients 3 months of age. The medicine should be avoided during pregnancy, particularly in the first trimester, unless deemed essential by a physician. It may be administered during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Klamentin (Amoxicillin/Clavulanic Acid) has officially documented interaction patterns that regulate its use with certain medicines and substances, as specified in regulatory labels. These interactions are categorized by their formal mechanism, which is critical for understanding administrative restrictions.

One primary pharmacokinetic interaction occurs with Probenecid, which inhibits the renal tubular secretion of the amoxicillin component. This documented interaction results in increased and prolonged plasma concentrations of amoxicillin.

Pharmacodynamic interactions are noted with several medicinal products. The co-administration of Oral Anticoagulants (such as Warfarin) may formally increase the prolongation of prothrombin time and INR, requiring appropriate monitoring. Use with Allopurinol is associated with an increased incidence of skin rash. Furthermore, this antibiotic may reduce the efficacy of Combined Oral Contraceptives.

Regarding restrictions, anti-peristaltic drugs are formally contraindicated if the patient develops antibiotic-associated colitis. A specific population constraint requires that the medication be avoided if Infectious Mononucleosis is suspected, due to the high risk of rash. Regarding food, administration with a meal is documented to enhance the absorption of the clavulanate component. Certain formulations contain phenylalanine, which must be considered for patients with Phenylketonuria.

Mechanism of Action

Klamentin operates via two separate, synergistic pharmacodynamic domains to mediate antibacterial activity.

Cell Wall Synthesis Inhibition

This domain is mediated by Amoxicillin, a beta-lactam antibiotic. It targets bacterial penicillin-binding proteins (PBPs)—transpeptidases essential for constructing the peptidoglycan layer of the bacterial cell wall. Amoxicillin acts by irreversibly binding to and inhibiting these PBPs. This molecular interaction initiates a downstream cascade, resulting in compromised cell wall structure, osmotic instability, and rapid bacterial cell lysis. The physiological consequence of this mechanism is the direct elimination of susceptible bacterial organisms.

Enzyme-Mediated Resistance Blockade

This domain is mediated by Clavulanic acid, a beta-lactamase inhibitor. Clavulanic acid acts as a suicide inhibitor, engaging bacterial beta-lactamase enzymes that would otherwise hydrolyze the beta-lactam ring of Amoxicillin. By binding to and permanently inactivating these beta-lactamase enzymes, Clavulanic acid suppresses this key bacterial defense mechanism. This action permits Amoxicillin to maintain its molecular integrity and activity against organisms possessing the beta-lactamase enzyme, resulting in the expansion of the spectrum of bacterial organisms susceptible to the action of the combined drug.

Dosage and Administration Information

How to Use Klamentin: Official Administration Guidelines

Klamentin (Amoxicillin/Clavulanic Acid) is administered through two primary routes: oral (tablets and reconstituted suspension) and intravenous (IV) for more severe cases or surgical prophylaxis. The drug’s usage protocol is defined by specific fixed-interval schedules and mandatory intake conditions.

Dosing and Frequency

Standard adult dosing is typically based on the Amoxicillin component, often ranging from 500 mg to 875 mg and administered either every 12 hours (twice daily) or every 8 hours (three times daily), depending on the specific formulation and severity of the condition. For pediatric patients, the dose is determined based on body weight. Treatment is generally prescribed for short courses, usually 7 to 10 days, and should not be extended beyond 14 days without careful medical review.

Administration Requirements

Oral forms must be taken at the start of a meal. This requirement is a high-level procedural instruction intended to optimize the absorption of the clavulanic acid component and reduce potential gastrointestinal upset. Tablets should be swallowed whole; extended-release forms, in particular, must not be crushed, broken, or chewed. The powder for oral suspension requires reconstitution with water and must be shaken well before each measured dose.

Special Use Conditions

Dosing regimens require modification in patients with impaired renal function (CrCl le 30 mL/min), as the drug is primarily eliminated by the kidneys. For example, the 875 mg tablet strength is generally not recommended for this population. Due to the varying ratios of the two active ingredients, different formulations or strengths are considered non-substitutable on a milligram-to-milligram basis.

Recent Clinical Evidence

Research evidence / Overview of Studies for Klamentin

Evidence for Use in Respiratory Tract Infections

The research for this combination antibiotic includes a substantial number of Randomized Controlled Trials (RCTs) and systematic reviews. These studies examined the combination's use for conditions where the research explored outcomes related to acute otitis media (ear infections), severe rhinosinusitis (sinus infections), and various types of pneumonia. Researchers examined clinical endpoints, such as the timeframes observed for changes in fever or respiratory symptoms, and microbiological outcomes, which monitor the presence or absence of bacterial pathogens. Some systematic reviews indicate that in certain less severe cases like Community-Acquired Pneumonia, studies described mixed findings or limited difference in clinical resolution when the combination was compared to Amoxicillin alone.


Evidence for Use in Skin, Soft Tissue, and Dental Infections

Klamentin was evaluated in short-term RCTs for infections involving the skin, soft tissues, and underlying structures, including in dental settings. Studies focused on outcomes related to physical discomfort, such as observed changes in localized redness and swelling, and systemic or functional imbalance like fever. The evidence indicates that comparative evidence with other available agents is sometimes lacking for certain conditions, and research usually focuses on short time intervals following treatment.


Long-Term Studies and Follow-up

The research primarily focuses on short-term changes and acute responses over defined time intervals (typically 7 to 14 days). Follow-up durations were limited in most studies. Evidence contributes to understanding acute symptom patterns, but there is limited information for long-term outcomes regarding the durability of pathogen outcomes or the absence of recurrence over extended periods. Therefore, long-term effects are not fully established in the available core research.


What is Still Uncertain About Klamentin Research

Evidence quality varies across studies, and several key research gaps persist. Data for certain groups, such as very young infants or patients with certain severe co-morbidities, remain insufficient. Furthermore, the combination's evaluation against rapidly evolving, highly resistant bacteria (like Extended-Spectrum β-Lactamase-producing strains) requires continuous, ongoing research to fully characterize.

Key Studies & References

  1. Clinical Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by IDSA

Frequently Asked Questions (FAQ)

Common questions about Klamentin (FAQ)

Q: What is Klamentin used to treat?

Official product information indicates that Klamentin is prescribed for treating a number of specific bacterial infections, including acute bacterial sinusitis, acute otitis media, community-acquired pneumonia, as well as certain infections of the skin, soft tissues, and urinary tract. Official information suggests that this medicine is effective only against susceptible bacteria.

Q: Is a rash a sign of an allergic reaction to Klamentin?

A rash is a documented, uncommon side effect of this medicine. However, official warnings state that a rash that progresses or occurs with other symptoms, such as swelling, fever, or blistering, can be a sign of a serious hypersensitivity reaction. In such a case, seeking guidance from a healthcare provider promptly is recommended in official documentation.

Q: Do Klamentin side effects improve after stopping the medicine?

Most common side effects, such as nausea and diarrhea, are generally considered transient and are expected to resolve after the medication is stopped. Conversely, official documents indicate that certain rare but serious side effects, such as liver dysfunction, may have a delayed onset or persist for some time after the course is finished. Therefore, continued professional monitoring may be considered based on the specific side effect.

Q: How soon after starting Klamentin should I expect to feel better?

Clinical study data indicates that treatment for certain infections should continue for at least 48 to 72 hours beyond when the patient’s symptoms have resolved. While a patient’s experience may vary, this suggests that a positive clinical response is typically observed within a few days of beginning therapy. The full prescribed course of treatment is intended to be followed as directed by a healthcare provider.

Q: What is the recommended storage temperature for Klamentin liquid suspension?

The official storage requirement for the reconstituted liquid suspension is refrigeration. The product must be stored at a cold temperature, typically between 2 C and 8 C. Official instructions indicate that the suspension is not to be frozen, and any unused portion must be discarded after 10 days, as specified in the official patient information.

Q: Is it safe to drive or operate machinery while taking Klamentin?

Official warnings in regulatory documents advise against driving or operating machinery unless the individual is feeling completely well. This is because side effects such as dizziness and headache may occur. The presence of these effects could potentially affect motor skills or cognitive ability.

Q: Is Klamentin considered a broad-spectrum or narrow-spectrum antibiotic?

Klamentin is a combination antibiotic designed to act against a wide range of bacteria. The clavulanic acid component, which blocks bacterial resistance enzymes, expands the spectrum of organisms the medicine is effective against. This mechanism allows it to treat infections caused by bacteria that are resistant to amoxicillin alone.

Q: Are there any different formulations of Klamentin, like chewable or liquid?

Yes, official dosage form information indicates that this medicine is manufactured in several formulations. These typically include film-coated tablets, oral suspension (liquid), and chewable tablets. Each formulation has its own administration requirements that should be followed.

Q: Is the brand name Klamentin the same as the generic version?

Official information states that different formulations and strengths of this medicine are considered non-substitutable on a milligram-to-milligram basis. This is due to variations in the ratio of the two active ingredients. Regulatory information suggests that confirmation with a healthcare provider or pharmacist may be necessary to ensure appropriate use.

Q: Why does Klamentin sometimes cause more digestive issues than other antibiotics?

Official clinical study data and warnings note that gastrointestinal adverse effects, such as diarrhea, are more commonly reported with this combination drug than with amoxicillin alone. This increased effect is linked to the clavulanic acid component of the medicine. This is why official instructions generally require the medicine to be taken at the start of a meal.

Q: Is Klamentin effective against all types of bacteria?

No, like all antibiotics, official documents state that Klamentin is only effective against susceptible bacterial organisms. Furthermore, prolonged use should be monitored, as it may result in the overgrowth of bacteria or fungi that are not susceptible to the medicine.

Q: What happens if I stop taking Klamentin before the full prescription is finished?

Official guidance emphasizes that treatment should be continued for the entire duration prescribed by a healthcare provider. Stopping the course early can result in the failure to fully eradicate the infection. This action may also increase the risk of the surviving bacteria developing resistance to the medicine.

Q: What is the risk of antibiotic resistance with Klamentin?

The possibility of superinfections with non-susceptible organisms must be considered during therapy, according to regulatory documents. Adherence to the full prescribed duration is generally emphasized in official materials for this reason. Failure to complete the full course can contribute to the development of bacterial resistance.

Q: Is Klamentin safe to use during pregnancy?

This medicine is assigned to FDA Pregnancy Category B. Official documents state that it should be used during pregnancy only when it is clearly needed. The decision to use it should be made by a healthcare provider after weighing the potential benefits against any potential risks.

Q: Can Klamentin be used by women who are breastfeeding?

Official information indicates that both active ingredients pass into human milk in small amounts. It is generally considered compatible with breastfeeding, but monitoring the infant for signs of adverse reactions, such as rash, diarrhea, or unusual restlessness, is noted in official documentation. A healthcare provider should be contacted if concerns arise.

Q: Are there any specific foods or drinks that should be avoided while taking Klamentin?

Official patient information notes that no specific foods or non-alcoholic drinks are formally restricted while taking this medicine. The only general requirement is to take the dose with a meal. This procedural instruction is intended to improve absorption and reduce the chance of stomach upset.

Q: Does Klamentin interact with alcohol?

Official sources report no severe drug-to-drug interaction between this medicine and alcohol. However, alcohol consumption may worsen common side effects like nausea and dizziness. Drinking alcohol may also hinder the body's overall ability to recover from the underlying infection.

Q: What is the proper method for disposing of unused Klamentin at home?

Regulatory medication disposal guidelines indicate that the most preferred method is to return unused or expired medicine to a pharmacy or official drug take-back location. If this is not possible, the medicine should be mixed with an undesirable substance (like used coffee grounds) and placed in a sealed container before disposal in the household trash.

Q: Can Klamentin cause a temporary change in tooth color in children?

Official patient information mentions that a change in tooth color, often appearing yellow, gray, or brown, has been reported, predominantly in children. This discoloration is usually temporary. In many cases, it can be lessened or removed with regular brushing or professional dental cleaning.

Q: Is it safe to take vitamins or herbal supplements while on Klamentin?

Official health guidance notes that complementary medicines, herbal remedies, and nutritional supplements are often not tested for interactions with prescription drugs. Therefore, consultation with a healthcare provider or pharmacist is noted as important before starting any such products while on this medicine.

Q: What are the recommendations for using Klamentin if I miss a dose?

Official patient instructions state that if a dose is missed, it should be taken as soon as possible. If it is nearly time for the next scheduled dose, the missed dose should be skipped entirely, and the next dose should be taken at the regular time. Official instructions state that double or extra doses are not to be taken.

How should Klamentin be stored and disposed of?

Klamentin (Amoxicillin/Clavulanate Potassium) must be stored and disposed of according to official regulatory requirements to maintain stability and ensure safety.

Storage Conditions by Form

Form Storage Requirement Shelf-Life Constraint
Tablets Store at controlled room temperature (20 C to 25 C), protected from moisture and heat [3.3, 3.1]. Use until expiration date.
Reconstituted Suspension Must be kept refrigerated (2 C to 8 C) [2.1, 2.3]. Discard after 10 days [3.1].

All forms must be kept in their original, tightly closed container and stored out of the reach and sight of children [3.3, 3.7].

Disposal

Unused or expired Klamentin must be discarded following official disposal guidelines [3.1]. Do not flush the product down the toilet or throw it into the drain to prevent environmental contamination [2.4].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Klamentin found in:

A-Z Index: